Synthesis of a paclitaxel isomer: C-2-Acetoxy-C-4-Benzoate paclitaxel

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2227-2230

  Chen, Shu Hui ^a,d   Farina, Vittorio ^b,d   Vyas, Dolatrai M ^d   Doyle, Terrence W ^c,d  

^a ELI LILLY AND COMPANY   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Vion Pharmaceuticals Incorporated   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C 2 ACETOXY C 4 BENZOATE PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOPATHOGENIC EFFECT; DRUG CONFORMATION; DRUG EFFECT; DRUG SYNTHESIS; MICROTUBULE ASSEMBLY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; DRUG DESIGN; INDICATORS AND REAGENTS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 0032544157     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00383-7     Document Type: Article

References (30)

1. 1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. J. Am. Chem. Soc. 1971, 95, 2325.
2. 2. Rowinsky, E. K.; Donehower, R. C. New Engl. Med. 1995, 332, 1004.
3. 3. (a) Schiff, P. B.; Horwitz, S. B. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 1561.
4. (b) Schiff, P. B.; Fant, J.; Horwitz, S. B. Nature 1979, 277, 665.
5. 4. For recent reviews, see (a) Taxane Anticancer Agents: Basic Science and Current Status; Georg, G. I.; Chen, T. C.; Ojima, I.; Vyas, D. M., Eds.; ACS Symposium Series 583; American Chemical Society: Washington, DC, 1995.
6. (b) The Chemistry and Pharmacology of Paclitaxel; Farina, V., Ed.; Elsevier: Amsterdam, 1995.
7. (c) Paclitaxel in Cancer Treatment; McGuire, W. P.; Rowinsky, E. K. Eds.; Marcel Dekker, Inc.; New York, 1995.
8. 5. BMS approaches to C-2 modifications: (a) Chen, S. H.; Farina, V.; Wei, J. M.; Long, B. H.; Fairchild, C.; Mamber, S. W.; Kadow, J. F.; Vyas, D. M.; Doyle, T. W. Bioorg. Med. Chem. Lett. 1994, 4, 479.
9. (b) Gao, Q.; Wei, J. M.; Chen, S. H. Pharm. Res. 1995, 12, 337.
10. 6. Other approaches to the C-2 analogs: (a) Chaudhary, A. G.; Gharpure, M. M.; Rimoldi, J. M.; Chordia, M. D.; Gunatilaka, A. A. L.; Kingston, D. G. I.; Grover, S.; Lin, C. M.; Hamel, E. J. Am. Chem. Soc. 1994, 116, 4097.
11. (b) Georg, G. I.; Harriman, G. C. B.; Ali, S. M.; Datta, A.; Hepperle, M.; Himes, R. H. Bioorg. Med. Chem. Lett. 1995, 5, 115.
12. (c) Georg, G. I.; Ali, S. M.; Boge, T. C.; Falborg, L.; Park, H.; Mejillano, M.; Himes, R. H. Bioorg. Med. Chem. Lett. 1995, 5, 259.
13. (d) Pulicani, J.-P.; Bezard, D.; Bourzat, J.-D.; Bouchart, H.; Zucco, M.; Deprez, D.; Commercon, A. Tetrahedron Lett. 1994, 35, 9717.
14. (e) Ojima, I.; Duclos, O.; Zucco, M.; Bissery, M-C.; Vrignaud, P.; Riou, J. F.; Lavelle, F. J. Med. Chem. 1994, 37, 2602.
15. (f) Nicolaou, K. C.; Renaud, J.; Nantermet, P. G.; Couladouros, E. A.; Guy, R. K.; Wrasidlo, W. J. Am. Chem. Soc. 1995, 117, 2409. (f) see 8d.
16. 7. BMS approaches to C-4 modifications: (a) Chen, S. H.; Kadow, J. F.; Farina, V.; Fairchild, C. R.; Johnston, K. A. J. Org. Chem, 1994, 59, 6156.
17. (b) Chen, S. H.; Fairchild, C. R.; Long, B. H. J. Med. Chem. 1995, 38, 2263.
18. (c) Chen, S. H.; Wei, J. M.; Long, B. H.; Fairchild, C.; Carboni, J.; Mamber, S. W.; Rose, W. C.; Johnston, K.; Casazza, A. M.; Kadow, J. F.; Farina, V.; Vyas, D. M.; Doyle, T. W. Bioorg. Med. Chem. Lett. 1995, 5, 2741.
19. (d) Chen, S. H. Tetrahedron Lett. 1996, 37, 3935.
20. 8. Other approaches to the C-4 analogs: (a) Neidigh, K. A.; Gharpure, M. M.; Rimoldi, J. M.; Kingston, D. G. I.; Jiang, Y. Q.; Hamel, E. Tetrahedron Lett. 1994, 35, 6839.
21. (b) Chordia, M. D.; Chaudhary, A. G.; Kingston, D. G. I.; Jiang, Y. Q.; Hamel, E. Tetrahedron Lett. 1994, 35, 6843.
22. (c) Georg, G. I.; Ali, S. M.; Boge, T. C.; Datta, A.; Falborg, L.; Himes, R. H. Tetrahedron Lett. 1994, 35, 8931.
23. (d) Holton, R. A.; Kim, Seocchan; Suzuki, Y. PCT Patent: WO94/17051
24. 9. (a) Holton, R. A. Presented at the 203rd Meeting of the American Chemical Society, San Francisco, CA 1991; Abstract No. ORGN 0355.
25. (b) Holton, R. A.; Biediger, R. J.; Boatman, P. D. Semisynthesis of Taxol and Taxotere. In Taxol®: Science and Applications; Suffness, M., Ed.; CRC: New York, 1995; pp 97-121.
26. 10. (a) For the preparation of β-lactam 13, see: Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C. M.; Brigaud, T. Tetrahedron 1992, 34, 6985.
27. (b) Ojima, I.; Zucco, M.; Duclos, O.; Kuduk, S. D.; Sun, C. M.; Park, Y. H. Bioorg. Med. Chem. 1993, 3, 2479.
28. +): 854.3389, found: 854.3421.
29. 12. All of the new compounds described in this paper were characterized by proton NMR and high resolution mass spectra.
30. 13. Swindell, C. S.; Krauss, N. E.; Horwitz, S. B.; Ringel, I. J. Med. Chem. 1991, 34, 1176.